Literature DB >> 27914742

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.

Rory D de Vries1, Nella J Nieuwkoop1, Mark Pronk1, Erwin de Bruin1, Geert Leroux-Roels2, Elisabeth G W Huijskens3, Rob S van Binnendijk4, Florian Krammer5, Marion P G Koopmans1, Guus F Rimmelzwaan6.   

Abstract

Influenza viruses are responsible for substantial morbidity and mortality during seasonal epidemics. Vaccination is the most effective method to prevent infection, however due to antigenic drift of the viral surface protein hemagglutinin (HA), annual influenza virus vaccination is required. In addition to seasonal viruses, certain (avian) influenza A viruses of other subtypes, like H5N1 or H7N9, cause sporadic zoonotic infections. Therefore, the availability of game-changing novel vaccines that induce "universal" immune responses to a wide variety of influenza A virus subtypes is highly desirable. The quest for universal influenza vaccines has fueled the interest in broadly-reactive antibodies specific for the stalk of hemagglutinin (HA) and biological activities of antibodies other than direct virus neutralization, like antibody-dependent cellular cytotoxicity (ADCC). In the present study, we investigated the ADCC response upon influenza virus vaccination and infection in humans using a robust ADCC assay that is based on the use of recombinant HA and a continuous NK cell line that expresses FcγRIII (CD16). This assay offers advantages over existing methods, like ease to perform and possibilities to standardize. We showed that HA-specific ADCC mediating antibodies are induced by vaccination with adjuvanted trivalent seasonal and monovalent H1N1pdm09 inactivated vaccines, and by infection with H1N1pdm09 virus. In addition, the use of chimeric influenza HA with a H1 stem but antigenically irrelevant head domain derived from an avian virus allowed detection of H1-stalk-specific ADCC mediating antibodies. This assay will facilitate the assessment of ADCC mediating serum antibodies after (universal) influenza vaccination or infection and may define ADCC activity as a correlate of (cross-) protection in the future.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Antibody dependent cellular cytotoxicity; Influenza virus; Natural killer cells

Mesh:

Substances:

Year:  2016        PMID: 27914742     DOI: 10.1016/j.vaccine.2016.11.082

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

2.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

Review 3.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

4.  Impact of the Innovative Medicines Initiative on vaccine development.

Authors:  Philippe Denoel; Patricia Londoño-Hayes; Magda Chlebus; Magdalena Rodriguez de Azero
Journal:  Nat Rev Drug Discov       Date:  2018-06-01       Impact factor: 84.694

5.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

Review 6.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

7.  One Step Forward in the Road Toward a Universal Influenza Vaccine.

Authors:  Octavio Ramilo; Rosa Rodriguez-Fernandez; Asuncion Mejias
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

8.  Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

Authors:  James D Allen; Hyesun Jang; Joshua DiNapoli; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

9.  Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

Authors:  Rory D de Vries; Nella J Nieuwkoop; Fiona R M van der Klis; Marion P G Koopmans; Florian Krammer; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

10.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.